442 related articles for article (PubMed ID: 15095227)
1. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.
Woods CW; Cheng AC; Fowler VG; Moorefield M; Frederick J; Sakoulas G; Meka VG; Tenover FC; Zwadyk P; Wilson KH
Clin Infect Dis; 2004 Apr; 38(8):1188-91. PubMed ID: 15095227
[TBL] [Abstract][Full Text] [Related]
2. Influence of in vitro susceptibility phenotype against thrombin-induced platelet microbicidal protein on treatment and prophylaxis outcomes of experimental Staphylococcus aureus endocarditis.
Dhawan VK; Yeaman MR; Bayer AS
J Infect Dis; 1999 Nov; 180(5):1561-8. PubMed ID: 10515816
[TBL] [Abstract][Full Text] [Related]
3. The role of vancomycin in the treatment paradigm.
Stevens DL
Clin Infect Dis; 2006 Jan; 42 Suppl 1():S51-7. PubMed ID: 16323121
[TBL] [Abstract][Full Text] [Related]
4. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
[TBL] [Abstract][Full Text] [Related]
5. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Aug; 46(33):765-6. PubMed ID: 9272582
[TBL] [Abstract][Full Text] [Related]
6. The first pediatric case of Staphylococcus aureus with heterogenous resistant to vancomycin endocarditis in Thailand.
Phongsamart W; Srifeungfung S; Tiensasitorn C; Vanprapar N; Chearskul S; Chokephaibulkit K
J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S264-8. PubMed ID: 16856450
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
Madrigal AG; Basuino L; Chambers HF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
[TBL] [Abstract][Full Text] [Related]
8. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
[TBL] [Abstract][Full Text] [Related]
9. Health care-associated endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.
Chi CY; Lauderdale TL; Wang SM; Wu JM; Yang YJ; Liu CC
J Clin Microbiol; 2008 Feb; 46(2):810-3. PubMed ID: 18077634
[TBL] [Abstract][Full Text] [Related]
10. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
Mariani PG; Sader HS; Jones RN
J Antimicrob Chemother; 2006 Aug; 58(2):481-3. PubMed ID: 16847029
[No Abstract] [Full Text] [Related]
11. Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Sep; 46(35):813-5. PubMed ID: 9310213
[TBL] [Abstract][Full Text] [Related]
12. Reduced susceptibility of Staphylococcus aureus to vancomycin--Japan, 1996.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Jul; 46(27):624-6. PubMed ID: 9218648
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
Nagura J; Kijima K; Kurazono M; Takahata S; Sugano T; Tanaka Y; Hirai Y; Yamada K; Takayama Y; Shitara E; Yonezawa M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3526-8. PubMed ID: 16048975
[TBL] [Abstract][Full Text] [Related]
14. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid.
Corne P; Marchandin H; Macia JC; Jonquet O
Scand J Infect Dis; 2005; 37(11-12):946-9. PubMed ID: 16308242
[TBL] [Abstract][Full Text] [Related]
15. Evidence of less severe aortic valve destruction after treatment of experimental staphylococcal endocarditis with vancomycin and dexamethasone.
Siaperas P; Pefanis A; Iliopoulos D; Katsarolis I; Kyroudi-Voulgari A; Donta I; Karayiannakos P; Giamarellou H
Antimicrob Agents Chemother; 2001 Dec; 45(12):3531-7. PubMed ID: 11709335
[TBL] [Abstract][Full Text] [Related]
16. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.
Lodise TP; McKinnon PS; Levine DP; Rybak MJ
Antimicrob Agents Chemother; 2007 Oct; 51(10):3731-3. PubMed ID: 17664322
[TBL] [Abstract][Full Text] [Related]
17. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
Kelley PG; Gao W; Ward PB; Howden BP
J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
[TBL] [Abstract][Full Text] [Related]
18. [Use of vancomycin in the treatment of severe Staphylococcus aureus infection. Description of 3 cases].
Campelli A; Mantero E; Fabbri A; Nahum M; Ferraris R; Di Noto C
Minerva Med; 1984 Feb; 75(8):385-90. PubMed ID: 6709217
[TBL] [Abstract][Full Text] [Related]
19. Staphylococcus aureus with reduced susceptibility to vancomycin in a dialysis graft.
Perla RJ; Knutson EL; Fontana JL
Clin Infect Dis; 2005 Aug; 41(4):566-7. PubMed ID: 16028171
[No Abstract] [Full Text] [Related]
20. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
Sakoulas G; Moellering RC
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
